Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HepaGam B with antiviral therapy in hepatitis B liver transplant patients
NCT00722332Phase 4Completed
- Sponsor
- Cangene Corporation
- Start
- Feb 2008
- Primary completion
- Oct 2013
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 2
01
Overview
Phase 4, open-label, single-arm trial of hepatitis B immune globulin in hepatitis B (HBV), sponsored by Cangene Corporation. Primary endpoint: Efficacy of HepaGam B in combination with antiviral therapy at 15 months. Started Feb 2008; status: completed.
02
Drugs
hepatitis B immune globulin
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT00722332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00722332.